title: Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials.
authors.affiliation: Charité, Campus Virchow Klinikum, Medizinische Klinik m.S. Hämatologie und Onkologie, Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: P D
authors.initials: PD
authors.lastname: le Coutre
authors.affiliation: Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Department of Haematology, SA Pathology, University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
authors.affiliation: Centre Hospitalier Universitaire de Bordeaux, Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Bordeaux, France.
authors.forename: F-X
authors.initials: FX
authors.lastname: Mahon
authors.affiliation: Division of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
authors.forename: D-W
authors.initials: DW
authors.lastname: Kim
authors.affiliation: Department of Hematology and IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of California at San Francisco School of Medicine, San Francisco, CA, USA.
authors.forename: N P
authors.initials: NP
authors.lastname: Shah
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: K
authors.initials: K
authors.lastname: Gooden
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: N
authors.initials: N
authors.lastname: Wallis
authors.affiliation: Division of Cancer Medicine, Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Cortes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000069439:Dasatinib / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000139:chemically induced* / Q000453:epidemiology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D000069439:Dasatinib